AVEI has a thread, and they do make catheters, but not for the aorta... see the blurb below.
I mention AVEI because Im convinced that you don't make money in biotech by buying what YOU like, but must follow larger trends and look for people or events that can move the market... Kam and Landis are currently very influential because of the success of their fund. Kam knows a lot about cardiology, AVEI is his top choice, and so for that reason alone, I would tend to buy AVEI at this point rather than EVTI. But I dont own either...I do own SNUS, AFFX, INCY and AGPH, for instance, but I'm avoiding device companies for now...too tricky for me.
"Its prospectus says Arterial Vascular Engineering AVEI "designs, develops, manufactures and markets a variety of stent systems and balloon angioplasty catheters for the treatment of coronary artery disease." The catheters are inflated within a partially blocked artery to expand the blood vessel. But in one-third to half of the 370,000 balloon angioplasties performed in 1993 in the U.S., there was re-closure of the artery.
The stents, now Arterial's big seller (77% of revenues), are made of a stainless steel mesh fitted over a balloon. Upon inflation after angioplasty, the mesh permanently expands, and is left in place, preventing re-closure in seven eighths of applications.
Neither of Arterial's product lines has been FDA-approved for sale in the U.S.